This site is intended for Healthcare Professionals only.

Evorel products may witness supply disruptions

Date:

Share post:

Theramex, the manufacturer of Evorel products, said there will be an intermittent supply shortages of Evorel 75, Evorel Conti in June due to rising demand.

The firm has clarified that it expects the stock levels of the two products to stabilise by July.

The  pharmacists and healthcare professionals have been advised to get in touch with Alliance Healthcare to place their orders for Evorel portfolio of products.

Country Product Name Dates of Availability
The UK
  1. Evorel 25
  2. Evorel 50
  3. Evorel 75
  4. Evorel 100
  5. Evorel Conti

6. Evorel Sequi

  1. Available
  2. Available
  3. Supply shortage expected for the final two weeks of June.
  4. Available
  5. Available from mid-June 2020. Possible intermittent supply shortages throughout June.
  6. Available
 

 

In February, Theramex restarted the supply of the Evorel portfolio of products. Since then it has  supplied a total of over half a million packs of Evorel 25, Evorel 50, Evorel 75, Evorel 100 and Evorel Conti to the UK market.

It has now relaunched Evorel Sequi, Evorel 25, Evorel 50, Evorel 75, and Evorel 100. These products are currently available in the market with sufficient supply.

The company further noted: “We will be restocking Evorel Conti in mid-June. It is possible we will experience intermittent supply shortages throughout the month due to high demand.

“There will also be a period of supply shortage for Evorel 75 from the middle to the end of June. We hope to stabilise stock levels for both products by July.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

PDA opposes DiCE guidance on online prescribing for GLP-1 agonist

PDA has withheld its endorsement of the DiCE guidance due to concerns over patient safety The Pharmacist's Defence Association...

Locum Pharmacist acquires 30-hour Moorside Pharmacy

The new owner plans to run Moorside Pharmacy on a hands-on basis and introduce additional services for the...

Breakthrough: Cabotegravir shows 88% reduction in HIV-1 incidence

Recommended by NICE and approved by the MHRA, Cabotegravir 600 mg long-acting injection is the first injectable treatment...

Why Community Pharmacy Must Embrace Innovation? Insights from Pharmacists

Future of community pharmacy: Pharmacists highlight the significance of embracing innovation and collaboration to improve efficiency and patient...